UBS Group »

Arrivent Biopharma shares owned by UBS Group

Quarter-by-quarter ownership of Arrivent Biopharma (AVBP) shares owned by UBS Group from 13F filings

Historical chart of UBS Group investment in Arrivent Biopharma

Tip: Access up to 7 years of quarterly data

All positions including Arrivent Biopharma held by UBS Group consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Arrivent Biopharma by UBS Group

Quarter filed Position value Share count Share price at filing
2024-03-31 $177k 9.9k 17.86

More positions owned by UBS Group

Spdr S&p 500 Etf Tr Tr Unit Call Option (SPY)
Microsoft Corporation Call Option (MSFT)
Apple Call Option (AAPL)
NVIDIA Corporation Call Option (NVDA)
Ishares Tr Russell 2000 Etf Call Option (IWM)
Invesco Qqq Tr Unit Ser 1 Call Option (QQQ)
Amazon Call Option (AMZN)
Ubs Group SHS Call Option (UBS)
JPMorgan Chase & Co. Call Option (JPM)
Alphabet Cap Stk Cl A Call Option (GOOGL)
Meta Platforms Cl A Call Option (META)
Broadcom Call Option (AVGO)
Visa Com Cl A Call Option (V)
Alphabet Cap Stk Cl C Call Option (GOOG)
UnitedHealth Call Option (UNH)

View all positions for UBS Group

Top funds holding Arrivent Biopharma

Hillhouse Capital Advisors
OrbiMed Advisors
FMR
Octagon Capital Advisors
Suvretta Capital Management
Sofinnova Ventures
Novo A/S
General Catalyst Group Management
Sc China Holding
BlackRock
Vanguard Group
Cormorant Asset Management
Perceptive Advisors
Geode Capital Management
State Street Corporation

View all funds holding Arrivent Biopharma